MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329621 | Name: Lenapenem

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lenapenem, also known as carbapenem, is a broad-spectrum, carbapenem antibiotic with bactericidal activity. Lenapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. This inhibition weakens the bacterial cell wall and leads to lytic cell death in a wide range of Gram-positive and Gram-negative aerobic and anaerobic pathogens

Chemical Structure

Lenapenem
Lenapenem
CAS#149951-16-6

Theoretical Analysis

MedKoo Cat#: 329621

Name: Lenapenem

CAS#: 149951-16-6

Chemical Formula: C18H29N3O5S

Exact Mass: 399.1828

Molecular Weight: 399.51

Elemental Analysis: C, 54.12; H, 7.32; N, 10.52; O, 20.02; S, 8.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lenapenem; carbapenem;
IUPAC/Chemical Name
(4R,5S,6S)-3-(((3S,5S)-5-((R)-1-hydroxy-3-(methylamino)propyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
InChi Key
PZLOCBSBEUDCPF-YJIVIRPOSA-N
InChi Code
InChI=1S/C18H29N3O5S/c1-8-14-13(9(2)22)17(24)21(14)15(18(25)26)16(8)27-10-6-11(20-7-10)12(23)4-5-19-3/h8-14,19-20,22-23H,4-7H2,1-3H3,(H,25,26)/t8-,9-,10+,11+,12-,13-,14-/m1/s1
SMILES Code
C[C@@H]1[C@@H]2[C@@H]([C@H](O)C)C(N2C(C(O)=O)=C1S[C@H]3C[C@@H]([C@H](O)CCNC)NC3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 399.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E. Carbapenems. J Chemother. 2013 Feb;25(1):1-17. doi: 10.1179/1973947812Y.0000000032. Review. PubMed PMID: 23433439. 2: Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014 Dec;27(6):479-83. doi: 10.1097/QCO.0000000000000109. Review. PubMed PMID: 25259809. 3: Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014 Aug;74(12):1315-33. doi: 10.1007/s40265-014-0267-8. Review. PubMed PMID: 25091170; PubMed Central PMCID: PMC4258832. 4: Pacifici GM, Allegaert K. Clinical pharmacology of carbapenems in neonates. J Chemother. 2014 Apr;26(2):67-73. doi: 10.1179/1973947813Y.0000000110. Epub 2013 Dec 6. Review. PubMed PMID: 24090536. 5: Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci. 2014 Sep;1323:22-42. doi: 10.1111/nyas.12537. Review. PubMed PMID: 25195939. 6: Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clin Infect Dis. 2014 Oct 15;59(8):1113-22. doi: 10.1093/cid/ciu587. Epub 2014 Jul 21. Review. Erratum in: Clin Infect Dis. 2015 Jan 1;60(1):175. Clin Infect Dis. 2015 Jan 1;60(1):175. PubMed PMID: 25048853. 7: Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22. Review. PubMed PMID: 21859938; PubMed Central PMCID: PMC3195018. 8: Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012 May;18(5):263-72. doi: 10.1016/j.molmed.2012.03.003. Epub 2012 Apr 3. Review. PubMed PMID: 22480775. 9: Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013 Apr;80(4):225-33. doi: 10.3949/ccjm.80a.12182. Review. PubMed PMID: 23547093; PubMed Central PMCID: PMC3960994. 10: Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care. 2014 Jun 27;18(3):229. doi: 10.1186/cc13949. Review. PubMed PMID: 25041592; PubMed Central PMCID: PMC4075344. 11: Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis. 2015 May 5;2(2):ofv050. doi: 10.1093/ofid/ofv050. eCollection 2015 May 5. Review. PubMed PMID: 26125030; PubMed Central PMCID: PMC4462593. 12: Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012 Jan;39(1):11-5. doi: 10.1016/j.ijantimicag.2011.08.018. Epub 2011 Nov 1. Review. PubMed PMID: 22047702. 13: Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013 Feb;11(2):159-77. doi: 10.1586/eri.12.162. Review. PubMed PMID: 23409822. 14: Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012 Dec;67(12):2793-803. doi: 10.1093/jac/dks301. Epub 2012 Aug 21. Review. PubMed PMID: 22915465. 15: Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28. Review. PubMed PMID: 24872346. 16: van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3. Review. PubMed PMID: 23290507; PubMed Central PMCID: PMC3947910. 17: Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11. doi: 10.1128/AAC.01230-13. Epub 2013 Aug 5. Review. PubMed PMID: 23917322; PubMed Central PMCID: PMC3811454. 18: Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19(2):223-38. Review. PubMed PMID: 22894617. 19: Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther. 2013 Apr;11(4):383-93. doi: 10.1586/eri.13.14. Review. PubMed PMID: 23566148. 20: Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review. PubMed PMID: 23074314.